Sol-Gel Technologies Ltd.
SLGLAbout the company
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Investment snapshot
Positive
1
BUY / PASS
Neutral / negative
3 / 12
NEUTRAL / FAIL
Median fair value
$2.67
-95.2% vs price
Models with upside
0 / 17
Positive margin of safety
Key risk
All 13 investors flag SLGL's valuation
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2328 (Top 75.2%) | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | -2962.2% | N/A | N/A | N/A | -1457.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | Annual history · FY 2025 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-19 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✗ 28▾
All 13 investors flag SLGL's valuation
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio6.7x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-4.4%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-4.4%, ROC=-76.1%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)476.9x✗Dreman< 8xPrice / Book Value per Share6.7x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-3.9%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=0.2%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=6.7x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePrice / FCF per Share558.4x✗Ackman<= 25Price vs. Trailing Low1060% of trailing low ($5.20)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-3.40%; #3712/6340 (top 58.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.1264; #4597/6449 (top 71.3%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share6.73x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.1074; #4299/5247 (top 81.9%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization+0.15%; #2512/4519 (top 55.6%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-26.37%; #4261/6202 (top 68.7%)✗OshaughnessyTop 10% of eligible cross-section - Valuation models0% pass✗ 2▾
SLGL overvalued: all 2 models price fair value below $55.12 (median $2.67)
Munger fair value$1.80✗Munger-2962.2% margin vs $55.12Ackman fair value$3.54✗Ackman-1457.1% margin vs $55.12 - Profitability6% pass✓ 5✗ 30▾
15 of 16 flag SLGL's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)5/12 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)1/12 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-32.7%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-38.9% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-6.1M✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-26.9%✗Lynch> 15%EBIT / Enterprise Value-4.4%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-4.4%, ROC=-76.1%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-20.48%✗PiotroskiROA > 0ROA Change YoY-29.52% -> -20.48% (delta: +9.04%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=1.08%, ROA=-20.48%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY✗PiotroskiImproved YoYPre-Tax Income / Revenue✗Dreman>= 8%Net Income / Shareholders' Equity-26.9%✗Dreman> 12%Margin of SafetyP/B=6.7x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-44.7% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePositive Net Income Frequency1/11 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-38.9%✗Ackman>= 15%Net Income / Shareholders Equity-26.9%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-1885.8% (2023) -> -38.9% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendrevenue up, operating margin -1885.8% -> -38.9%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-3.40%; #3712/6340 (top 58.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-26.86%; #3840/5226 (top 73.5%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.2085; #4271/5884 (top 72.6%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR-46.8% over 5 years✗Neff7%-20% annualizedPositive Diluted-EPS Years4/10 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Verdicts7% pass✓ 1✗ 13▾
Split decision: 12 FAIL · 3 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #2328✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (2/8)•SleepNEUTRAL (4/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag SLGL's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest Coverage✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities4.37✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDA✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Growth13% pass✓ 4✗ 9▾
7 of 8 flag SLGL's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthN/A (no inventory)✓LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR-32.9% CAGR over 6 years✗Dreman> 5% annualizedPositive Net Income Frequency1/11 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth68.0%✓Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendrevenue up, operating margin -1885.8% -> -38.9%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR17.2%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR-46.8% over 5 years✗Neff7%-20% annualized - Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag SLGL's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio4.37✓Graham>= 2.0ROIC (3-5 yr avg)-328.2%✗Buffett> 10%ROIC - WACC-338.2%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-76.1%✗Greenblatt> 25%Current Ratio Change YoY5.92 -> 4.37✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.32x -> 0.65x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities4.37✓Dreman> 1.5Return on Invested Capital✗Munger> 15%ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)✗SleepROIC > 12% in a majority of years - Cash Flow30% pass✓ 4✗ 8▾
7 of 10 flag SLGL's cash flow — Buffett, Dreman, Pabrai +4 more
Free Cash Flow Proxy$-6.1M✗BuffettPositive and growingFCF Positive and Growing$0.3M✓LynchPositive and growingOperating Cash Flow$0.3M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=1.08%, ROA=-20.48%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)476.9x✗Dreman< 8xP/E or FCF YieldFCF Yield=0.2%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive1/11 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap0.2%✗Ackman>= 4%Price / FCF per Share558.4x✗Ackman<= 25Positive Operating Cash Flow frequency1/11 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$0.3M✓Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization+0.15%; #2512/4519 (top 55.6%)✗OshaughnessyTop 10% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 0.0% of shares last year, 0.0% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
| Metric | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|
| Market Cap | $180.5Mcurrent | $213.1Mest. | $390.0Mest. | $1.2Best. | $1.6Best. |
| Revenue | $19.4M↑68% | $11.5M↑642% | $1.6M↓60% | $3.9M↓88% | $31.3M |
| Operating Income | -$7.5M↑37% | -$12.0M↑59% | -$29.3M↓80% | -$16.2M↓648% | $3.0M |
| Net Income | -$6.1M↑42% | -$10.6M↑61% | -$27.2M↓83% | -$14.9M↓563% | $3.2M |
| EPS (Diluted) | $-2.19↓476% | $-0.38↑62% | $-1.01↓55% | $-0.65↓564% | $0.14 |
| Gross Margin | — | — | — | — | — |
| Operating Margin | -38.9%↑63% | -104.1%↑94% | -1885.8%↓351% | -418.3%↓4514% | 9.5% |
| ROE | -26.9%↑27% | -36.7%↑48% | -70.5%↓99% | -35.4%↓710% | 5.8% |
| Total Debt | -- | -- | -- | -- | -- |
| Shareholders' Equity | $22.8M↓21% | $28.9M↓25% | $38.6M↓8% | $42.2M↓24% | $55.6M |
| Current Ratio | 4.37↓26% | 5.92↓35% | 9.10↓30% | 12.93↑165% | 4.88 |
| Debt / Equity | — | — | — | — | — |
| Operating Cash Flow | $322.0K↑102% | -$13.9M↑22% | -$17.7M↓87% | -$9.5M↓23% | -$7.7M |
| Free Cash Flow | $275.0K↑102% | -$13.9M↑22% | -$17.9M↓85% | -$9.7M↓23% | -$7.8M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
SLGL vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |